ORIG3N is a biotechnology company developing a breakthrough disease-modeling platform targeting rare genetically inherited diseases. By advancing screening projects using iPSC-derived differentiated cells and rapidly delivering the resulting data to inform therapeutic decisions, ORIG3N will replace trial and error guess work of treating disease and enable longer, healthier lives. The founders are serial entrepreneurs who's previous venture, ArtusLabs, was acquired by PerkinElmer in 2011.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/17/15 | $3,100,000 |
Harris & Harris Group Hatteras Venture Partners Mountain Group Capital | undisclosed | |
| 12/17/15 | $12,500,000 | Series A |
DEFTA Partners Harris & Harris Group Hatteras Venture Partners Laboratory Corporation of America MGC Venture Partners Syno Capital | undisclosed |
| 06/27/17 | $20,000,000 |
180 Degree Capital DEFTA Partners Hatteras Venture Partners  KTB-KORUS Fund LabCorp MGC Venture Partners Spectrum Health Ventures Syno Capital | undisclosed | |
| 07/12/18 | undisclosed | Series B |
180 Degree Capital Alexandria Venture Investments DEFTA Partners Haitong International Securities Hatteras Venture Partners LabCorp MMIC Investment Holdings Mountain Group Capital Spectrum Health Ventures Vectr Ventures | undisclosed |
